Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3307656 | 0.92 | MEN1 (0.68) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL17694973 | 0.85 | MEN1 (0.63) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL17945300 | 0.85 | MEN1 (0.63) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL19219087 | 0.85 | MEN1 (0.63) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL17694981 | 0.85 | MEN1 (0.63) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL10168729 | 0.84 | CYP19A1 (0.62) | KMT2AMEN1NTSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24590021 | 0.83 | KMT2A (0.61) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL10968230 | 0.82 | MEN1 (0.61) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL4808050 | 0.82 | MEN1 (0.61) | KMT2AMEN1NTSR1ADORA1ADORA2A | |
| SCHEMBL3165362 | 0.82 | MEN1 (0.57) | KMT2AMEN1NTSR1ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423044-B2 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-20040110780-A1 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-06-10 | — | — | US | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | KMT2A 1940/4885MEN1 2833/4885NTSR1 2891/4885 |
| US-20040110780-A1 | Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, GCKR | KMT2A 3613/4885MEN1 4215/4885NTSR1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.